PARIS – Swedish registry report analyzes key clinical outcomes in more than 36,000 consecutive acute MI patients who received newer-generation...
MALMO, SWEDEN – Recognition of key risk factors warrants early screening ultrasound.
The obesity paradox makes a showing in the risk of all-cause death.
A reanalysis of the ATLAS ACS 2-TIMI 51 trial separated fatal and nonfatal events.
PARIS – “Given the high bleeding risk, single antiplatelet therapy seems to be a good option for these patients,” said Dr. Ulf Landmesser.
WASHINGTON – The preferred evaluation – intravascular ultrasound – was not used.
Andexanet alfa approval puts factor Xa inhibitors in the same ballpark as dabigatran, reversible with idarucizumab.
SAN DIEGO – Consider increased monitoring of renal function in certain patients.
We’ve come a long way in clinical trial representation of women, but there’s more work to do.
More than one-third of patients with an MI before age 50 and an LDL cholesterol of at least 160 mg/dL meet criteria for FH.
ORLANDO – Idarucizumab, reversal agent for the anticoagulant dabigatran, worked fine in patients with renal dysfunction.
SEATTLE – Thromboelastometry can play a role in identifying bariatric surgery patients at risk for VTE.
ECG patches may provide an inexpensive and noninvasive way to screen for asymptomatic atrial fibrillation in high-risk people.
The results “imply that there is a significantly unmet need for effective VTE prophylaxis in both the inpatient and outpatient continuum of care...
ORLANDO – “I believe this trial is going to change practice.” – Valentin Fuster, MD
ORLANDO – Mortality and major adverse cardiovascular events were cut 15%, but that’s not all.
ANAHEIM, CALIF. – Danish national study is the first of its kind and found fivefold increased all-cause mortality.
"Our take home message from this study is that sexual activity can be regarded as safe, even in cardiac patients."
Obese people have shorter life spans and spend more of their lives dealing with cardiovascular disease.
